# Efficacy and Safety of ALT-801 in the Treatment of Obesity

> **NCT05295875** · PHASE2 · COMPLETED · sponsor: **Altimmune, Inc.** · enrollment: 391 (actual)

## Conditions studied

- Obesity/Overweight

## Interventions

- **DRUG:** ALT-801
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05295875
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295875, "Efficacy and Safety of ALT-801 in the Treatment of Obesity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05295875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*